Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) is a specialty pharmaceutical company dedicated to developing and commercializing innovative medicines designed to solve critical healthcare challenges. By focusing on patient-centric solutions, Aquestive aims to improve the lives of individuals managing complex diseases. The company's core area of expertise lies in the Central Nervous System (CNS) and severe allergic reactions, including anaphylaxis.
Core Business and Products
Aquestive Therapeutics leverages its proprietary drug delivery technologies to create novel oral treatments that offer convenient alternatives to invasive, conventional therapies. The company’s commercial product portfolio includes:
- Sympazan Oral Film - A treatment for seizures associated with Lennox-Gastaut Syndrome.
- Suboxone Sublingual Film - Utilized in opioid addiction management.
- Exservan Oral Film - A medication for Amyotrophic Lateral Sclerosis (ALS).
- Zuplenz - An antiemetic to prevent nausea and vomiting.
Pipeline and Recent Developments
Aquestive's robust pipeline includes late-stage candidates such as:
- Libervant Buccal Film - Positioned to address seizure clusters in epilepsy patients.
- AQST-108 - A sublingual film for the treatment of anaphylaxis.
- AQST-305 - A developing solution for severe allergic reactions.
The company has made significant strides with its proprietary PharmFilm® technology, enhancing drug delivery effectiveness and patient compliance. Aquestive collaborates with other pharmaceutical entities to bring these advanced treatments to market. Recent achievements include pivotal trials and regulatory submissions that underscore the company's commitment to addressing unmet medical needs.
Financial Overview
Aquestive Therapeutics predominantly earns its revenue from the United States through product sales and licensing agreements. The company’s latest financial reports indicate stable growth prospects, driven by its innovative product offerings and strong pipeline.
Partnerships and Market Presence
Aquestive actively partners with leading pharmaceutical firms to expand its reach and impact. The company's collaborations enable the development and commercialization of breakthrough treatments, further establishing its presence in the global pharmaceutical landscape.
For more information, recent updates, and investor inquiries, please visit the company’s official website or contact their investor relations team.
Aquestive Therapeutics, Inc. (NASDAQ:AQST) reported Q3 2021 financials with total revenues of $13.3 million, up from $8.3 million in Q3 2020. The company improved net loss to $14.6 million or $0.37 per share, versus $16.6 million or $0.49 per share a year ago, driven by increased revenue and lower costs. The firm anticipates FDA feedback on its NDA for Libervant™ by December 23, 2021, and continues development of AQST-109 for allergic reactions, showing promising Phase 1 results. Updated full-year revenue guidance ranges from $47 to $49 million.
Aquestive Therapeutics (NASDAQ: AQST) reported positive results from the Phase 1 clinical trial of AQST-109, an innovative sublingual epinephrine delivery system for anaphylaxis. The study demonstrated a median time to peak concentration (Tmax) of 15 minutes or less, comparable to traditional autoinjectors like EpiPen® and Auvi-Q®. Key clinical measures for safety and efficacy were within expected ranges, with no serious adverse events reported. AQST-109 aims to provide a needle-free alternative, enhancing patient accessibility and safety. A pivotal pharmacokinetic study is anticipated in 2022.
Aquestive Therapeutics (NASDAQ: AQST) has announced it will report its Q3 2021 results on November 2, 2021, after market close. A conference call for investors is scheduled for November 3, 2021, at 8:00 a.m. ET. The company's focus is on developing innovative pharmaceutical products, including Libervant™ (diazepam) Buccal Film. The press release highlights potential risks related to COVID-19's impact on clinical trials, regulatory timelines, and market access. Additionally, the company’s collaboration with other pharmaceutical firms aims to advance drug development.
Aquestive Therapeutics (AQST) announced a bridge waiver agreement with lenders, allowing the deferral of the first principal payment due under its 12.5% Senior Secured Notes to March 30, 2023. This amendment includes a $2.7 million payment to note holders in quarterly installments starting March 30, 2022. CEO Keith Kendall highlighted lender support and the potential for a $30 million debt access upon FDA approval of Libervant, a novel treatment for refractory epilepsy. The FDA has set a PDUFA date of December 23, 2021, for Libervant’s approval.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced participation in three investor conferences in September 2021, aimed at showcasing its innovative pharmaceutical solutions. The events include H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, Lake Street Virtual Best Ideas Growth Conference on September 14, and the 2021 Cantor Virtual Global Healthcare Conference on September 30 at 8:00 a.m. ET. Webcast replays will be available for 90 days post-event. For further details, visit investors.aquestive.com.
Aquestive Therapeutics (AQST) announced a $30 million capital access contingent on FDA approval for Libervant, an innovative oral diazepam for managing seizure clusters. The company amended its agreement with lenders, extending the term for six months to June 30, 2022, allowing for a $10 million draw post-FDA approval and an additional $20 million upon U.S. market access. The FDA has set a PDUFA goal date of December 23, 2021, for Libervant's resubmitted NDA. Aquestive remains confident in its non-invasive product's potential, aligning with its broader strategy to address unmet patient needs.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) announced its participation in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference on August 11, 2021, at 11:30 am ET. The panel discussion will focus on advancing novel epilepsy targets. The company is known for its innovative pharmaceuticals, including Sympazan®, an oral film for clobazam. It is committed to addressing unmet medical needs through proprietary technologies like PharmFilm®. Forward-looking statements regarding their product Libervant™ highlight potential risks, including regulatory uncertainties and market access challenges.
Aquestive Therapeutics (AQST) announced significant developments, including the FDA's acceptance of the NDA for Libervant with a PDUFA goal date of December 23, 2021. The company is also on track to report top-line data from its Phase 1 study for AQST-109 in the second half of 2021. Full-year revenue guidance has been increased to $46-$48 million, reflecting a solid performance, especially in Sympazan. Total revenues for Q2 2021 were $15.3 million, with a net loss of $12.4 million.
Aquestive Therapeutics (NASDAQ: AQST) will announce its second-quarter results on August 3, 2021, after market close. An investor conference call is scheduled for August 4, 2021, at 8:00 a.m. ET. The company is known for its innovative pharmaceutical products, including Sympazan and the development of Libervant among other candidates. Investors can access the conference call details through the company's website. The report is expected to cover business updates and strategies, particularly regarding ongoing product developments.
Aquestive Therapeutics (AQST) announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for managing seizure clusters. The PDUFA goal date is set for December 23, 2021. If approved, Libervant will be the first orally delivered diazepam product for this indication. The company is preparing for a potential commercial launch in early 2022. Libervant aims to provide a non-invasive and consistent alternative to current treatments for refractory epilepsy patients.
FAQ
What is the current stock price of Aquestive Therapeutics (AQST)?
What is the market cap of Aquestive Therapeutics (AQST)?
What does Aquestive Therapeutics, Inc. specialize in?
What are some of the key products in Aquestive Therapeutics' portfolio?
What is the PharmFilm® technology?
What is Libervant Buccal Film used for?
Where does Aquestive Therapeutics derive most of its revenue from?
What is AQST-108?
How does Aquestive Therapeutics collaborate with other pharmaceutical companies?
What recent developments has Aquestive Therapeutics achieved?
Who are the primary partners in Aquestive Therapeutics' recent offering?